Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17959066 | 1.00 | ESR2 (0.49) | ESR2NR1H2MAPK1RIPK1HDAC1 | |
| SCHEMBL3276386 | 0.93 | ESR2 (0.51) | ESR2NR1H2MAPK1RIPK1HDAC1 | |
| SCHEMBL30405260 | 0.83 | RIPK1 (0.48) | ESR2NR1H2MAPK1RIPK1HDAC1 | |
| SCHEMBL856288 | 0.83 | RIPK1 (0.48) | ESR2NR1H2MAPK1RIPK1HDAC1 | |
| SCHEMBL17959028 | 0.81 | HPGD (0.41) | RIPK1ABHD6LMNASMN1; SMN2NPC1 | |
| SCHEMBL17991072 | 0.81 | ESR2 (0.44) | ESR2NR1H2MAPK1RIPK1LMNA | |
| SCHEMBL24265586 | 0.81 | NR1H2 (0.62) | ESR2NR1H2MAPK1RIPK1HDAC1 | |
| SCHEMBL29574152 | 0.81 | NR1H2 (0.62) | ESR2NR1H2MAPK1RIPK1HDAC1 | |
| SCHEMBL1263385 | 0.81 | ESR2 (0.63) | ESR2NR1H2MAPK1RIPK1HDAC1 | |
| SCHEMBL2986459 | 0.80 | ESR2 (0.65) | ESR2NR1H2MAPK1RIPK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304904-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20230357216-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2023-11-09 | — | — | US | disclosed |
| US-11702412-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357216-A1 | BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC4 | ESR2 3331/4885NR1H2 228/4885MAPK1 3600/4885 |
| US-12304904-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC2, HDAC4 | ESR2 3331/4885NR1H2 228/4885MAPK1 3600/4885 |
| US-11702412-B2 | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC2, HDAC4 | ESR2 3331/4885NR1H2 228/4885MAPK1 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.